The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer
Open accessAbstract
BACKGROUND: It is becoming increasingly evident that microRNAs (miRNAs) are associated with the development and progression of prostate cancer (PCa). METHODS: We examined the hypothesis that plasma miRNA levels can differentiate patients by aggressiveness in 82 PCa patients. Taqman based quantitative RT‐PCR assays were performed to measure copy number of target miRNAs. RESULTS: miR‐20a was significantly overexpressed in plasma from patients with stage 3 tumors compared to stage 2 or below (P = 0.03). The expression levels for miR‐20a and miR‐21 were significantly increased in patients with high risk CAPRA scores (16,623 and 1,595 copies, respectively). Significantly increased miR‐21 and miR‐145 expression were observed for patients with intermediate or high risk D'Amico scores compared to patients with low risk scores (P = 0.047 and 0.011, respectively). The relapse rates for CAPRA scores ranged from 1.9% for low risk to 9.5% for intermediate risk and to 22.2% for high risk patients (P = 0.023). For D'Amico scores, the relapse rates ranged from 0.0% for low risk to 7.4% for intermediate risk and 17.6% for high risk patients (P = 0.039). Expression of miR‐21 and miR‐221 significantly differentiated patients with intermediate risk from those with low risk CAPRA scores (AUC = 0.801, P = 0.002). Four miRNAs (miR‐20a, miR‐21, miR‐145, and miR‐221) could also distinguish high versus low risk in PCa patients by D'Amico score with an AUC of 0.824. CONCLUSIONS: These preliminary data suggest that altered plasma miRNAs may be useful predictors to distinguish PCa patients with varied aggressiveness. Further larger studies to validate this promising finding are warranted. Prostate 72:1469–1477, 2012. © 2012 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combinatorial microRNA target predictions
Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., MacMenamin, P., da Piedade, I., Gunsalus, K. C., Stoffel, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1536 · Cited by 4,603
Cited by
Murray, D. D., Suzuki, K., Law, M., Trebicka, J., Neuhaus, J., Wentworth, D., Johnson, M., Vjecha, M. J., Kelleher, A. D., Emery, S., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139981 · Cited by 2,740
Clinical relevance of circulating cell-free microRNAs in cancer
Schwarzenbach, H., Nishida, N., Calin, G. A., & Pantel, K. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.5 · Cited by 969
The role of exosomes in cancer metastasis
Steinbichler, T. B., Dudás, J., Riechelmann, H., & Skvortsova, I.-I. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.02.006 · Cited by 389
MicroRNAs as Potential Biomarkers in Cancer: Opportunities and Challenges
Lan, H., Lu, H., Wang, X., & Jin, H. (2015) · BioMed Research International · doi:10.1155/2015/125094 · Cited by 330
The Potential of MicroRNAs as Prostate Cancer Biomarkers
Fabris, L., Ceder, Y., Chinnaiyan, A. M., Jenster, G. W., Sorensen, K. D., Tomlins, S., Visakorpi, T., & Calin, G. A. (2016) · European Urology · doi:10.1016/j.eururo.2015.12.054 · Cited by 311
Metadata
- Authors
- Shen, J., Hruby, G. W., McKiernan, J. M., Gurvich, I., Lipsky, M. J., Benson, M. C., & Santella, R. M.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2012-02
- Volume
- 72
- Issue
- 13
- Pages
- 1469-1477
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W1966434915
- Cited by
- 183
- References
- 1
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. https://app.cochat.ai/papers/10.1002/pros.22499
- The paper
- Shen, J., Hruby, G. W., McKiernan, J. M., Gurvich, I., Lipsky, M. J., Benson, M. C., & Santella, R. M. (2012). Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. The Prostate. https://doi.org/10.1002/pros.22499
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.